About
Minimally Invasive Device for Heart Failure
Levron is developing a novel autonomic integrated diagnostic and therapeutic minimally invasive device intended to be used with cardiac failure patients. The company's device integrates diagnosis and treatment, shifts fluids from the lung, and reduces cardiac workloads. The device provides adaptive treatment for NYHA stage 3 heart failure, eliminating lung congestion.
Identity
| Name | Levron Cardiovascular |
|---|---|
| Slug | levron-cardiovascular |
| Type / kind | startup |
| Source _id | aKjJ7aoTvuRlgeykLBF4jxuhnoakQLYa363z8bpMhIi3qBnyYpUPFY |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Yokne'am Illit |
| HQ address | HaKidma St 28, Yokne'am Illit, 20692, Israel |
Web & social
| Website | https://www.levron-medical.com/ |
|---|---|
| https://www.linkedin.com/company/77039918 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & SubstancesImplants
Target customers
Healthcare & Life SciencesMedical Devices IndustryMedical EquipmentHealthcarePatients
Business models
B2C
Tags
therapeutic-devicesheart-failuremedical-devicescardiologyminimally-invasive
Funding
| Total raised | $2.2M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}